CN105294838A - 一种抗菌肽及其应用 - Google Patents
一种抗菌肽及其应用 Download PDFInfo
- Publication number
- CN105294838A CN105294838A CN201510608404.3A CN201510608404A CN105294838A CN 105294838 A CN105294838 A CN 105294838A CN 201510608404 A CN201510608404 A CN 201510608404A CN 105294838 A CN105294838 A CN 105294838A
- Authority
- CN
- China
- Prior art keywords
- antibacterial peptide
- antibacterial
- peptide
- lys lys
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003910 polypeptide antibiotic agent Substances 0.000 title claims abstract description 36
- 241000894006 Bacteria Species 0.000 claims abstract description 11
- 230000003115 biocidal effect Effects 0.000 claims description 5
- 241000192125 Firmicutes Species 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 18
- 244000063299 Bacillus subtilis Species 0.000 abstract description 8
- 150000001413 amino acids Chemical group 0.000 abstract description 7
- 230000003013 cytotoxicity Effects 0.000 abstract description 7
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 7
- 230000002949 hemolytic effect Effects 0.000 abstract description 6
- 241000191963 Staphylococcus epidermidis Species 0.000 abstract description 5
- 229940088710 antibiotic agent Drugs 0.000 abstract description 3
- RRBGTUQJDFBWNN-MUGJNUQGSA-N (2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2,6-diaminohexanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O RRBGTUQJDFBWNN-MUGJNUQGSA-N 0.000 abstract 1
- LXAARTARZJJCMB-CIQUZCHMSA-N Ala-Ile-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LXAARTARZJJCMB-CIQUZCHMSA-N 0.000 abstract 1
- RDLYUKRPEJERMM-XIRDDKMYSA-N Asn-Trp-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(O)=O RDLYUKRPEJERMM-XIRDDKMYSA-N 0.000 abstract 1
- CPYHLXSGDBDULY-IHPCNDPISA-N Asn-Trp-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O CPYHLXSGDBDULY-IHPCNDPISA-N 0.000 abstract 1
- 235000014469 Bacillus subtilis Nutrition 0.000 abstract 1
- 241000588724 Escherichia coli Species 0.000 abstract 1
- BQVUABVGYYSDCJ-UHFFFAOYSA-N Nalpha-L-Leucyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-UHFFFAOYSA-N 0.000 abstract 1
- ZPZNQAZHMCLTOA-PXDAIIFMSA-N Trp-Tyr-Ile Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CC=C(O)C=C1 ZPZNQAZHMCLTOA-PXDAIIFMSA-N 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 108010024607 phenylalanylalanine Proteins 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 23
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 230000001580 bacterial effect Effects 0.000 description 14
- 229920001184 polypeptide Polymers 0.000 description 14
- 101800003223 Cecropin-A Proteins 0.000 description 10
- 108010036176 Melitten Proteins 0.000 description 10
- HCQPHKMLKXOJSR-IRCPFGJUSA-N cecropin-a Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(N)=O)[C@@H](C)CC)C(C)C)[C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCCCN)C1=CC=CC=C1 HCQPHKMLKXOJSR-IRCPFGJUSA-N 0.000 description 10
- VDXZNPDIRNWWCW-UHFFFAOYSA-N melitten Chemical compound NCC(=O)NC(C(C)CC)C(=O)NCC(=O)NC(C)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)O)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(CO)C(=O)NC(C(=O)NC(C(C)CC)C(=O)NC(CCCCN)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-UHFFFAOYSA-N 0.000 description 10
- 239000008057 potassium phosphate buffer Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 206010018910 Haemolysis Diseases 0.000 description 5
- 230000008588 hemolysis Effects 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 230000003385 bacteriostatic effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000751182 Staphylococcus epidermidis ATCC 12228 Species 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 239000012930 cell culture fluid Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510608404.3A CN105294838B (zh) | 2015-09-22 | 2015-09-22 | 一种抗菌肽及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510608404.3A CN105294838B (zh) | 2015-09-22 | 2015-09-22 | 一种抗菌肽及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105294838A true CN105294838A (zh) | 2016-02-03 |
CN105294838B CN105294838B (zh) | 2018-07-03 |
Family
ID=55192737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510608404.3A Active CN105294838B (zh) | 2015-09-22 | 2015-09-22 | 一种抗菌肽及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105294838B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106008677A (zh) * | 2016-08-04 | 2016-10-12 | 遵义医学院 | 一种抗菌肽se37及其应用 |
CN106496306A (zh) * | 2016-11-09 | 2017-03-15 | 湖南科技学院 | 一种能抑制和杀灭多种耐药性细菌的抗菌肽 |
CN107383175A (zh) * | 2017-09-01 | 2017-11-24 | 遵义医学院 | 一种抗菌肽vk‑21及其应用 |
CN107903308A (zh) * | 2017-12-04 | 2018-04-13 | 遵义医学院 | 一种抗菌肽kk26及其应用 |
CN110330069A (zh) * | 2019-08-01 | 2019-10-15 | 南京中医药大学 | 一种高效便捷去除水相溶液中内毒素的清除剂及其制备 |
CN111909243A (zh) * | 2020-08-04 | 2020-11-10 | 武汉康湃特生物科技有限公司 | 一种抗菌肽和抗菌止痒药物组合物及应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101215325B (zh) * | 2003-10-17 | 2010-12-15 | 上海高科联合生物技术研发有限公司 | 一组抗菌肽及其制备方法和应用 |
CN103145802B (zh) * | 2012-09-13 | 2017-07-21 | 吉林大学 | 一种多肽类促感染试剂 |
CN102924574B (zh) * | 2012-10-26 | 2013-12-04 | 苏州康尔生物医药有限公司 | 抗菌肽lz1和该抗菌肽在制备抗菌药物中的用途 |
-
2015
- 2015-09-22 CN CN201510608404.3A patent/CN105294838B/zh active Active
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106008677A (zh) * | 2016-08-04 | 2016-10-12 | 遵义医学院 | 一种抗菌肽se37及其应用 |
CN106496306A (zh) * | 2016-11-09 | 2017-03-15 | 湖南科技学院 | 一种能抑制和杀灭多种耐药性细菌的抗菌肽 |
CN106496306B (zh) * | 2016-11-09 | 2019-10-29 | 湖南科技学院 | 一种能抑制和杀灭多种耐药性细菌的抗菌肽 |
US10603350B2 (en) | 2016-11-09 | 2020-03-31 | Hunan University Of Science And Engineering | Antimicobial peptides for inhibiting drug-resistant bacteria and uses thereof |
CN107383175A (zh) * | 2017-09-01 | 2017-11-24 | 遵义医学院 | 一种抗菌肽vk‑21及其应用 |
CN107383175B (zh) * | 2017-09-01 | 2019-07-05 | 遵义医学院 | 一种抗菌肽vk-21及其应用 |
CN107903308A (zh) * | 2017-12-04 | 2018-04-13 | 遵义医学院 | 一种抗菌肽kk26及其应用 |
CN107903308B (zh) * | 2017-12-04 | 2019-07-05 | 遵义医学院 | 一种抗菌肽kk26及其应用 |
CN110330069A (zh) * | 2019-08-01 | 2019-10-15 | 南京中医药大学 | 一种高效便捷去除水相溶液中内毒素的清除剂及其制备 |
CN111909243A (zh) * | 2020-08-04 | 2020-11-10 | 武汉康湃特生物科技有限公司 | 一种抗菌肽和抗菌止痒药物组合物及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN105294838B (zh) | 2018-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105294838A (zh) | 一种抗菌肽及其应用 | |
CN104151415B (zh) | 一种天然抗菌肽Alligatorin4及其应用 | |
CN102702333B (zh) | 抗耐药性病原菌感染多肽及其用途 | |
CN109553657A (zh) | 一种非完美两亲性肽w4及其制备方法和应用 | |
CN115960171A (zh) | 高稳定性Trp-pocket跨链交互型β-发卡抗菌肽及制备方法和应用 | |
CN102603885B (zh) | 防御素及其在制备抗菌药物中的应用 | |
CN106146643B (zh) | 人α‑防御素5改造体及其应用 | |
Miyasaki et al. | Sensitivity of periodontal pathogens to the bactericidal activity of synthetic protegrins, antibiotic peptides derived from porcine leukocytes | |
CN113214355B (zh) | 一种专杀真菌的抗菌肽gl4w及其制备方法和应用 | |
CN101215325B (zh) | 一组抗菌肽及其制备方法和应用 | |
Imran | Bacteriocin: An alternative to antibiotics | |
CN107043428A (zh) | 一种α螺旋结构的抗炎杂合抗菌肽及其制备方法和应用 | |
Wang et al. | Characterization of a Cathelicidin from the Colubrinae Snake, Sinonatrix annularis | |
CN100365018C (zh) | 一组抗菌肽及其制备方法和应用 | |
CN101942473A (zh) | 克氏原螯虾i型溶菌酶基因及其编码的溶菌酶与应用 | |
Han et al. | Co-production of multiple antimicrobial compounds by Bacillus amyloliquefaciens WY047, a strain with broad-spectrum activity | |
CN101182351A (zh) | 一组抗菌肽及其制备方法和应用 | |
CN105198979B (zh) | 一种海蛇改造体抗菌肽qha1及其制备方法和应用 | |
Conlon et al. | Peptides with potent cytolytic activity from the skin secretions of the North American leopard frogs, Lithobates blairi and Lithobates yavapaiensis | |
CN113999297A (zh) | 一种抗菌肽hrNCM及其制备方法与应用 | |
CN106589135B (zh) | 一种靶向抗菌肽及其制备方法和应用 | |
CN1634981B (zh) | 一组新的抗菌肽及其制备方法和应用 | |
CN106518999B (zh) | 基于微缩肽策略的抗菌肽ww及其制备方法和应用 | |
CN103193877B (zh) | 一种蛋白质及其在制备抗微生物产品中的应用 | |
CN111533788B (zh) | 一种靶向无乳链球菌的细胞穿透抗菌肽及制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Shan Yaming Inventor after: He Xiaoqiu Inventor after: Zhang Hao Inventor before: Shan Yaming Inventor before: He Xiaoqiu |
|
COR | Change of bibliographic data | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Shan Yaming Inventor after: Zhang Hao Inventor after: Guan Shanshan Inventor after: He Xiaoqiu Inventor before: Shan Yaming Inventor before: He Xiaoqiu Inventor before: Zhang Hao |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210224 Address after: Room 602, door 1, deputy building 3, Dahua science and technology new village, 42 Weixing Road, high tech Zone, Changchun City, Jilin Province, 130012 Patentee after: Changchun Matai Biotechnology Co.,Ltd. Address before: 221011a office area, 2 / F, North office building, Suzhou Avenue, Xuzhou Industrial Park, Jiawang District, Xuzhou City, Jiangsu Province Patentee before: XUZHOU MATAI BIOTECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230713 Address after: Room 13-013, 13th Floor, No.1 Jiankang Road, Torch Development Zone, Zhongshan City, Guangdong Province, 528436 Patentee after: Metom Technology (Zhongshan) Co.,Ltd. Address before: Room 602, door 1, deputy building 3, Dahua science and technology new village, 42 Weixing Road, high tech Zone, Changchun City, Jilin Province, 130012 Patentee before: Changchun Matai Biotechnology Co.,Ltd. |
|
TR01 | Transfer of patent right |